Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Kainic acid·Î À¯¹ßµÈ ½ÇÇèÀû °æ·Ã ÁßøÁõ¿¡ ´ë¸¸ PropofolÀÇ È¿°ú The Effects of Propofol on Kainic Acid Induced Status Epilepticus in Rats

´ëÇÑ°£ÁúÇÐȸÁö 1997³â 1±Ç 1È£ p.80 ~ 84
ä¼ö¾È, ±è¿ë¼ö, ÀÓÀμ®, À¯º´ÈÆ, ±è°æ¿ë,
¼Ò¼Ó »ó¼¼Á¤º¸
ä¼ö¾È ( Chae Soo-Ahn ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

±è¿ë¼ö ( Kim Yong-Soo ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÀÓÀμ® ( Lim In-Seok ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
À¯º´ÈÆ ( Yoo Byung-Hoon ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
±è°æ¿ë ( Kim Kyung-Yong ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ÇغÎÇб³½Ç

Abstract


Purpose : Propofol is an intravenous short acting agent frequently used in neuroanesthesia and successfully used to abort status epilepticus (SE). But some cases of epileptic seizures follow propofol-induced anesthesia with suggestion that propofol may aggressive seizures in seizure-prone patients. The aim of this study is to assess the clinical and histological effects of propofol on experimental SE.

Methods : SE was induced in 250-300 gm Sprague-Dawley rats with kainic acid (KA. 15 mg/kg/ip). To assess the effects of propofol on seizure-prone rats, propofol was given 15 min after the injection of KA before onset of seizures. To assess the effects of propofol as an anticonvulsant, it was given with 15 minutes of SE to other rats. Control rats were injected with saline in both groups. Histology was used to assess neuronal damage 2 weeks after SE.

Results : Propofol broke SE in all group 1 rats. The difference of the mean seizure latency between group 2 rats and control group rats is statiscally meaningful (p<0.01) ; seizures of group 2 rats were severe ; 2 rats died. Seizure induced hippocampal neuronal damage was less in rats treated with propofol compared to controls.

Conclusions : This study shows that propofol is a effective anticonvulsant and neuronal protector, but may be a proconvulsant in seizure-prone patients.

Å°¿öµå

Propofol; °æ·Ã ÁßøÁõ; Ç×°æ·ÃÁ¦; Àü±¸°æ·ÃÁ¦; ½Å°æ¿ø º¸È£
Propofol; Status epilepticus; Anticonvulsant; Proconvulsant; Neuronal protection

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS